Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 20/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557333 | 0.94 | AGTR2 (1.00) | AGTR2AGTR1CYP2C9CYP2B6 | |
| Buloxibutid SCHEMBL557591 | 0.89 | AGTR2 (1.00) | AGTR2AGTR1CYP2C9CYP2B6 | |
| Buloxibutid SCHEMBL26934181 | 0.88 | AGTR2 (0.98) | AGTR2AGTR1CYP2C9CYP2B6 | |
| Buloxibutid SCHEMBL30718088 | 0.88 | AGTR2 (0.98) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL557104 | 0.87 | AGTR2 (1.00) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL5214238 | 0.85 | AGTR2 (0.94) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL1718514 | 0.81 | AGTR2 (1.00) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL557741 | 0.81 | AGTR2 (1.00) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL6612215 | 0.81 | AGTR2 (0.75) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL3535512 | 0.80 | AGTR2 (1.00) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835471-B2 | Use of angiotensin II agonists | VICORE PHARMA AB | 2014-09-16 | — | — | US | claimed |
| US-20120035232-A1 | USE OF ANGIOTENSIN II AGONISTS | VICORE PHARMA AB | 2012-02-09 | — | — | US | claimed |
| US-7652054-B2 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2010-01-26 | — | — | US | claimed |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | VICORE PHARMA AB | 2009-12-31 | — | — | US | claimed |
| EP-1395566-B1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2007-09-12 | — | — | EP | claimed |
| CN-1529697-A | Tricyclic compounds useful as angiotensin II agonists | ά�ƶ�ҩ�﹫˾ | 2004-09-15 | — | — | CN | claimed |
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2004-08-26 | — | — | US | claimed |
| EP-1395566-A1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | Vicore Pharma AB (SE) | 2004-03-10 | — | — | EP | claimed |
| WO-2002096883-A1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2002-12-05 | — | — | WO | claimed |
| US-20150209332-A1 | Use of Angiotensin II Agonists | VICORE PHARMA AB (SE) | 2015-07-30 | — | — | US | disclosed |
| US-8835471-B2 | Use of angiotensin II agonists | VICORE PHARMA AB | 2014-09-16 | — | — | US | disclosed |
| US-8124638-B2 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20120035232-A1 | USE OF ANGIOTENSIN II AGONISTS | VICORE PHARMA AB | 2012-02-09 | — | — | US | disclosed |
| US-7652054-B2 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2010-01-26 | — | — | US | disclosed |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | VICORE PHARMA AB | 2009-12-31 | — | — | US | disclosed |
| EP-1395566-B1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | AGTR1, AGTR2, NPY2R | AGTR2 2/4885AGTR1 1/4885CYP2C9 1541/4885 |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | AGTR2, AGTR1, NPY4R | AGTR2 1/4885AGTR1 2/4885CYP2C9 1155/4885 |
| US-20120035232-A1 | USE OF ANGIOTENSIN II AGONISTS | AGTR1, AGTR2, REN | AGTR2 2/4885AGTR1 1/4885CYP2C9 2062/4885 |
| US-20150209332-A1 | Use of Angiotensin II Agonists | AGTR1, AGTR2, REN | AGTR2 2/4885AGTR1 1/4885CYP2C9 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.